Antisense Therapeutics lowers costs for MS treatment study

[MSUK]

Antisense Therapeutics lowers costs for multiple sclerosis treatment support study

Antisense Therapeutics (ASX: ANP) has significantly lowered the costs associated with its planned chronic toxicology study of the drug ATL1102.

The company now expects the study, which will support a potential future phase IIb study of ATL1102 in multiple sclerosis patients, to cost less than A300,000 to complete.

Importantly, Antisense is able to fund the study without it having a material effect on cash flow forecasts which cover planned activities well into 2014..... Read More - http://www.ms-uk.org/index.cfm/MSnews